收稿日期: 2022-08-10
网络出版日期: 2022-12-19
基金资助
国家自然科学基金(81501400);中央高水平医院临床科研业务费专项(北京大学第一医院院内交叉临床研究专项)(2022CR10)
Diagnostic values of urinary citrate for kidney stones in patients with primary gout
Received date: 2022-08-10
Online published: 2022-12-19
Supported by
National Natural Science Foundation of China(81501400);National High Level Hospital Clinical Research Funding(Interdepartmental Clinical Research Project of Peking University First Hospital)(2022CR10)
目的: 分析原发性痛风患者24 h尿液离子含量及其与肾结石的关系，探讨其在痛风合并肾结石诊断中的价值。方法: 回顾性分析2020年1月至2021年5月在北京大学第一医院风湿免疫科门诊连续就诊且资料完整的痛风患者，根据临床和超声资料，分析肾结石与尿液离子成分的相关性以及肾结石形成的危险因素。进一步以双能CT证实的肾尿酸盐结石为金标准，探讨尿液离子异常对于痛风合并肾尿酸盐结石的诊断价值。结果: 100例患者中80例超声发现下肢关节尿酸盐晶体沉积，61例超声发现肾结石，34例双能CT检查证实为尿酸盐结石。与超声检查无肾结石组患者相比，肾结石组的痛风病程更长[(48.7±26.6)个月vs. (84.0±30.6)个月，P=0.01]，24 h尿草酸总量更高[(20.1±9.6) mg vs. (28.6±20.7) mg，P=0.001]，24 h尿枸橼酸总量更低[(506.3±315.4) mg vs. (355.7±219.6) mg，P=0.001]。与双能CT无肾结石组患者相比，肾尿酸盐结石组痛风病程更长[(49.1±28.4)个月vs. (108.3±72.2)个月，P=0.001]，24 h尿草酸总量更高[(23.6±16.9) mg vs. (28.5±18.8) mg，P < 0.05]，24 h尿枸橼酸总量更低[(556.0±316.3) mg vs. (391.7±261.2) mg，P < 0.05]，平均血尿酸水平及24 h尿尿酸总量更高[(466.2±134.5) μmol/L vs. (517.2±18.1) μmol/L，P < 0.05；(1 518.1±893.4) mg vs. (1 684.2±812.1) mg，P < 0.05]。以病程、既往痛风发作频率、血尿酸、血肌酐及24 h尿草酸、枸橼酸、尿酸为自变量进行Logistic回归分析，结果显示长病程(OR=1.229，95%CI：1.062~1.522，P < 0.05)、高血尿酸(OR=1.137，95%CI：1.001~1.213，P=0.01)、低24 h尿枸橼酸总量(OR=0.821，95%CI：0.659~0.952，P=0.01)为痛风患者超声发现肾结石的危险因素；长病程(OR=1.201，95%CI：1.101~1.437，P=0.005)、高血肌酐(OR=1.145，95%CI：1.001~1.182，P=0.04)、低24 h尿枸橼酸总量(OR=0.837，95%CI：0.739~0.931，P=0.02)为痛风患者出现肾尿酸盐结石的危险因素。结论: 长病程、低24 h尿枸橼酸的痛风患者更容易出现肾结石。
关键词： 痛风; 肾结石; 枸橼酸; 超声检查; 双能电子计算机断层扫描
王昱 , 张慧敏 , 邓雪蓉 , 刘伟伟 , 陈璐 , 赵宁 , 张晓慧 , 宋志博 , 耿研 , 季兰岚 , 王玉 , 张卓莉 . 尿枸橼酸定量检测在原发性痛风患者肾结石诊断中的应用价值[J]. 北京大学学报（医学版）, 2022 , 54(6) : 1134 -1140 . DOI: 10.19723/j.issn.1671-167X.2022.06.013
Objective: To evaluate the relationship between 24 h urinary ion content and kidney stones, and to explore the diagnostic values of kidney stone in primary gout patients. Methods: Patients diagnosed with primary gout had ultrasound scanning of both feet and kidneys in Peking University First Hospital from Jan. 2020 to May 2021. Their clinical characteristics were compared between the positive and negative kidney stone groups, and the relationship between kidney stone and urinary ion composition were analyzed. Risk factors of kidney stone were analyzed. The explored diagnostic values were evaluated for urinary oxalate and citrate according with uric acid kidney stones by dual-energy computed tomography (DECT). Results: Among the 100 gouty patients, 80 patients had uric acid crystal deposition in lower joints of extremity by ultrasonography, 61 patients had kidney stone, and 34 had kidney uric acid stones by DECT. All the multiple kidney stones were proved as uric acid kidney stones by DECT. Compared with patients without kidney stone group proved by ultrasonography, patients with kidney stone had longer gouty duration [(48.7±26.6) months vs. (84.0±30.6) months, P=0.01], higher 24 h urinary oxalate [(20.1±9.6) mg vs. (28.6±20.7) mg, P=0.001] and lower 24 h urinary citrate [(506.3±315.4) mg vs. (355.7±219.6) mg, P=0.001]. Compared with the patients without kidney stone by DECT, the patients with uric acid kidney stone also had longer disease duration [(49.1±28.4) months vs. (108.3±72.2) months, P=0.001], higher 24 h urinary oxalate [(23.6±16.9) mg vs. (28.5±18.8) mg, P < 0.05], lower 24 h urinary citrate [(556.0±316.3) mg vs. (391.7±261.2) mg, P < 0.05], higher serum uric acid [(466.2±134.5) μmol/L vs. (517.2±18.1) μmol/L, P < 0.05] and higher 24 h urinary uric acid [(1 518.1±893.4) mg vs. (1 684.2±812.1) mg, P < 0.05]. Logistic regression analysis showed long gout disease duration (OR=1.229, 95%CI: 1.062-1.522, P < 0.05), high serum uric acid level (OR=1.137, 95%CI: 1.001-1.213, P=0.01), low 24 h urinary citrate (OR=0.821, 95%CI: 0.659-0.952, P=0.01) were all risk factors of kidney stones by ultrasonography. Also, long gout disease duration (OR=1.201, 95%CI: 1.101-1.437, P=0.005), high serum creatine uric level (OR=1.145, 95%CI: 1.001-1.182, P=0.04), low 24 h urinary citrate (OR=0.837, 95%CI: 0.739-0.931, P=0.02) were all risk factors of kidney uric acid stones by DECT. Conclusion: Long disease duration and low 24 h urinary citrate were risk factors for kidney stones.
Key words： Gout; Kidney stone; Citrate; Ultrasonography; Dual-energy computed tomography
| 1 | Wallace SL , Robinson H , Masi AT , et al. Preliminary criteria for the classification of the acute arthritis of primary gout[J]. Arthritis Rheum, 1977, 20 (3): 895- 900. |
| 2 | Filippou G , Pascart T , Iagnocco A . Utility of ultrasound and dual energy CT in crystal disease diagnosis and management[J]. Curr Rheumatol Rep, 2020, 22 (5): 15. |
| 3 | Skolarikos A , Straub M , Knoll T , et al. Metabolic evaluation and recurrence prevention for urinary stone patients: EAU guidelines[J]. Eur Urol, 2015, 67 (4): 750- 763. |
| 4 | Neogi T , Jansen TL , Dalbeth N , et al. 2015 gout classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative[J]. Ann Rheum Dis, 2015, 74 (10): 1789- 1798. |
| 5 | Gutierrez M , Schmidt WA , Thiele RG , et al. International consensus for ultrasound lesions in gout: Results of Delphi process and web-reliability exercise[J]. Rheumatology (Oxford), 2015, 54 (10): 1797- 1805. |
| 6 | 范兵, 王霄英, 邱建星, 等. 能谱CT与常规CT对泌尿系结石CT值的相关性分析[J]. CT理论与应用研究, 2016, 25 (4): 403- 408. |
| 7 | 《泌尿外科杂志(电子版)》编辑部. 泌尿系结石诊治指南解读(一)[J]. 泌尿外科杂志(电子版), 2010, 2 (4): 56- 57. |
| 8 | Richette P , Doherty M , Pascual E , et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout[J]. Ann Rheum Dis, 2020, 79 (1): 31- 38. |
| 9 | 王昱, 陈育青, 张蓓, 等. 原发性痛风患者24 h尿液化学成分分析与尿酸结石形成风险的研究[J]. 中华风湿病学杂志, 2018, 22 (3): 165- 170. |
| 10 | Tzelves L , Türk C , Skolarikos A . European Association of Urology urolithiasis guidelines: Where are we going?[J]. Eur Urol Focus, 2021, 7 (1): 34- 38. |
| 11 | Pearle MS , Goldfarb DS , Assimos DG , et al. Medical management of kidney stones: AUA guideline[J]. J Urol, 2014, 192 (2): 316- 324. |
| 12 | Nestler T , Nestler K , Neisius A , et al. Diagnostic accuracy of third-generation dual-source dual-energy CT: A prospective trial and protocol for clinical implementation[J]. World J Urol, 2019, 37 (4): 735- 741. |
| 13 | 张晓洁, 姜林娣. 痛风患者肾脏结石与关节部位尿酸盐晶体沉积的相关性[J]. 中国临床医学, 2017, 24 (5): 767- 769. |
| 14 | Siener R , Glatz S , Nicolay C , et al. Prospective study on the efficacy of a selective treatment and risk factors for relapse in recurrent calcium oxalate stone patients[J]. Eur Urol, 2003, 44 (4): 467- 474. |
| 15 | Mittal A , Tandon S , Singla SK , et al. In vitro inhibition of cal-cium oxalate crystallization and crystal adherence to renal tubular epithelial cells by Terminalia arjuna[J]. Urolithiasis, 2016, 44 (2): 117- 125. |
| 16 | 闫晓煜, 黄志红, 孟胜兰, 等. 24小时尿枸橼酸、草酸定量检测在泌尿系结石诊断中的应用[J]. 标记免疫分析与临床, 2018, 25 (5): 634- 668. |
| 17 | Smith LH . Diet and hyperoxaluria in the syndrome of idiopathic calcium oxalate urolithiasis[J]. Am J Kidney Dis, 1991, 17 (4): 370- 375. |
| 18 | Holmes RP , Goodman HO , Assimos DG . Contribution of dietary oxalate to urinary oxalate excretion[J]. Kidney Int, 2001, 59 (1): 270- 276. |
| 19 | Robijn S , Hoppe B , Vervaet BA , et al. Hyperoxaluria: A gut-kidney axis?[J]. Kidney Int, 2011, 80 (11): 1146- 1158. |
| 20 | Taylor EN , Curhan GC . Oxalate intake and the risk for nephroli-thiasis[J]. J Am Soc Nephrol, 2007, 18 (7): 2198- 2204. |
| 21 | Curhan GC , Taylor EN . 24 h uric acid excretion and the risk of kidney stones[J]. Kidney Int, 2008, 73 (4): 489- 496. |
| 22 | Kok DJ , Papapoulos SE , Bijvoet OL . Crystal agglomeration is a major element in calcium oxalate urinary stone formation[J]. Kidney Int, 1990, 37 (1): 51- 56. |
| 23 | Mandel EI , Taylor EN , Curhan GC . Dietary and lifestyle factors and medical conditions associated with urinary citrate excretion[J]. Clin J Am Soc Nephrol, 2013, 8 (6): 901- 908. |
| 24 | Domrongkitchaiporn S , Stitchantrakul W , Kochakarn W . Causes of hypocitraturia in recurrent calcium stone formers: Focusing on urinary potassium excretion[J]. Am J Kidney Dis, 2006, 48 (4): 546- 554. |
| 25 | Coe FL , Parks JH , Asplin JR . The pathogenesis and treatment of kidney stones[J]. N Engl J Med, 1992, 327 (16): 1141- 1152. |
| 26 | Ettinger B , Tang A , Citron JT , et al. Randomized trial of allopurinol in the prevention of calcium oxalate calculi[J]. N Engl J Med, 1986, 315 (22): 1386- 1389. |
| 27 | Ferraro PM , Curhan GC , D'Addessi A , et al. Risk of recurrence of idiopathic calcium kidney stones: Analysis of data from the lite-rature[J]. J Nephrol, 2017, 30 (2): 227- 233. |
| 28 | Levy FL , Adams-Huet B , Pak CY . Ambulatory evaluation of nephrolithiasis: An update of a 1980 protocol[J]. Am J Med, 1995, 98 (1): 50- 59. |
/
| 〈 |
|
〉 |
